Aditya K Gupta1, Maryse Paquet. 1. Department of Medicine, University of Toronto, Toronto, ON, Canada. agupta@execulink.com
Abstract
BACKGROUND: A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration. OBJECTIVE: To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate. METHODS: The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009-2011) and the Annual Meeting of the American Academy of Dermatology (2009-2012) were also searched. RESULTS: Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate. CONCLUSION: Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.
BACKGROUND: A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration. OBJECTIVE: To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate. METHODS: The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009-2011) and the Annual Meeting of the American Academy of Dermatology (2009-2012) were also searched. RESULTS: Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate. CONCLUSION:Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.
Authors: Andrew Blauvelt; Marc Brown; Kenneth B Gordon; Arthur Kavanaugh; Craig T Leonardi; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2013-09
Authors: Guochun Jiang; Erica A Mendes; Philipp Kaiser; Sumathi Sankaran-Walters; Yuyang Tang; Mariana G Weber; Greg P Melcher; George R Thompson; Amilcar Tanuri; Luiz F Pianowski; Joseph K Wong; Satya Dandekar Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: Shijie Cao; Sarah D Slack; Claire N Levy; Sean M Hughes; Yonghou Jiang; Christopher Yogodzinski; Pavitra Roychoudhury; Keith R Jerome; Joshua T Schiffer; Florian Hladik; Kim A Woodrow Journal: Sci Adv Date: 2019-03-27 Impact factor: 14.957
Authors: Yehua Jin; Chien-Hung Yeh; Christian A Kuttruff; Lars Jørgensen; Georg Dünstl; Jakob Felding; Swaminathan R Natarajan; Phil S Baran Journal: Angew Chem Int Ed Engl Date: 2015-09-29 Impact factor: 15.336